Name: Tirzepatide
Brand: Peptific
SKU: TIRZEPATIDE-10-MG
Availability: InStock

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its class, with Phase III data showing 22.5% mean body weight reduction at 72 weeks, the highest performance in obesity pharmacology trial history at publication.

GLP-1 Peptides

Tirzepatide

Tirzepatide is the first approved dual GIP/GLP-1 receptor agonist — a 39-amino-acid synthetic peptide on a novel non-GLP-1 backbone engineered to achieve balanced co-agonism at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor simultaneously. It is not a derivative of either native hormone but a designed dual agonist, a structural distinction with mechanistic implications for incretin pharmacology research. The Phase III data established tirzepatide as the highest-performing compound in obesity trial history at the time of publication. In SURMOUNT-1 (non-diabetic obesity, N=2,539), tirzepatide 15 mg weekly produced 22.5% mean body weight reduction at 72 weeks — a result that significantly exceeded matched semaglutide comparator data and approached the magnitude of bariatric surgical outcomes in a pharmacological trial. SURPASS trials across multiple T2D populations documented HbA1c reductions exceeding all prior GLP-1RA benchmarks. For mechanistic research, the dual GIP/GLP-1 agonism creates research questions that single-receptor agents cannot address: what is the relative contribution of GIP receptor activation to adipose tissue lipid handling, beta cell preservation, energy expenditure, and weight reduction compared to GLP-1R? Tirzepatide is the pharmacological tool for investigating these questions. For researchers studying dual incretin pharmacology, adipose tissue biology, pancreatic function, or the GIP/GLP-1 receptor interaction, tirzepatide is the most comprehensively validated dual receptor agonist in the published literature. This listing is for laboratory and preclinical research purposes only. Not for human or veterinary use.

Product Information

Shipping & Returns

Select Format

From $2,500.00

Tirzepatide-

$2,500.00

Product definition

What is Tirzepatide?

Tirzepatide (Mounjaro, Zepbound; Eli Lilly) is a 39-amino-acid acylated peptide on a novel amino acid backbone — it does not share the GLP-1 or GIP sequences, but is engineered to achieve high affinity at both receptors. A C20 fatty diacid chain enables albumin binding and weekly dosing via a ~5-day half-life. FDA approved in 2022 for T2D (Mounjaro) and in 2023 for obesity (Zepbound). The mechanistic novelty is the GIP receptor contribution. Prior GLP-1RAs had established that GLP-1R activation alone produces significant weight reduction. The GIP receptor's role in adipose tissue metabolism — specifically, its expression on adipocytes and effects on lipid uptake, storage, and energy expenditure — had been debated before tirzepatide demonstrated that co-activating GIPR alongside GLP-1R produces incremental metabolic benefit beyond GLP-1R activation alone. The SURPASS and SURMOUNT phase 3 programs (>20,000 participants) constitute the most comprehensive dual incretin pharmacology dataset in the research literature.

Research context

How is Tirzepatide described in the research literature?

Tirzepatide activates both GIP receptors (GIPR) and GLP-1 receptors (GLP-1R) with balanced affinity, combining two distinct incretin signaling pathways. GIP receptor activation contributes to adipose tissue lipid handling, pancreatic beta cell protection, and energy partitioning; GLP-1R activation contributes to gastric emptying delay, hypothalamic satiety signaling, and insulin secretion. The dual activation produces additive or synergistic metabolic effects beyond either receptor alone.

Compound profile

Key facts about Tirzepatide

Class: Dual GIP/GLP-1 receptor agonist
Amino acids: 39
Molecular weight: ~4,813 Da
Half-life: ~5 days (albumin-bound in vivo)
Modification: C20 fatty diacid conjugate at Lys26 via linker
CAS: 2023788-19-2
Clinical status: FDA-approved (Mounjaro, Zepbound)
Research category: Dual incretin pharmacology, obesity, T2D, adipose tissue biology
Storage: Lyophilized: −20°C. Reconstituted: 2–8°C, use within 30 days

Research areas

What research areas is Tirzepatide associated with?

First approved dual GIP/GLP-1 receptor agonist — distinct novel peptide backbone, not a modified GLP-1 or GIP
SURMOUNT-1 Phase III: 22.5% mean body weight reduction at 72 weeks — highest obesity trial result at time of publication
SURPASS-2: superior HbA1c reduction vs. semaglutide 1 mg in head-to-head Phase III T2D trial
GIP receptor activation contributes adipose biology dimension absent from single-GLP-1R agonists
~5-day half-life enables weekly research dosing protocols
Most comprehensively validated dual incretin compound with Phase III dataset across obesity + T2D programs

Research audience

Who researches Tirzepatide?

Tirzepatide is used by researchers studying dual incretin pharmacology, adipose tissue biology, beta cell function, GIP receptor signaling, and metabolic obesity mechanisms. It is essential for protocols requiring a pharmacological tool to study GIP/GLP-1 co-agonism or to compare dual-receptor versus single-receptor incretin effects.

Preclinical research overview

What does the preclinical literature say about Tirzepatide?

Tirzepatide was developed by Eli Lilly following the clinical success of the GLP-1RA class, with the hypothesis that adding GIP receptor engagement to GLP-1R agonism would produce incremental metabolic benefit. The GIP receptor's role had been debated — some researchers hypothesized GIPR antagonism might improve outcomes, others hypothesized agonism would add benefit. Tirzepatide's Phase III results definitively resolved the question in favor of agonism for weight outcomes. The SURMOUNT-4 extension trial documented weight regain upon tirzepatide withdrawal, confirming the metabolic effects are pharmacologically maintained rather than permanent — an important finding for ongoing obesity biology research about the role of sustained incretin signaling. In preclinical models, tirzepatide's dual receptor pharmacology is studied to dissect the relative adipose tissue contributions of GIPR versus GLP-1R activation — using receptor-specific agonists and antagonists as research controls to attribute observed effects to the appropriate receptor pathway. This mechanistic dissection work constitutes an active area of metabolic research.

Common questions

Frequently asked about Tirzepatide

What research questions is tirzepatide uniquely suited to answer?

Tirzepatide is the tool for studying GIP/GLP-1 co-agonism pharmacology — specifically the incremental contribution of GIPR activation to adipose tissue lipid handling, beta cell preservation, and weight reduction beyond what GLP-1R agonism alone produces. Comparing tirzepatide to a matched GLP-1RA (like semaglutide) in the same model system allows attribution of differential effects to the GIPR component.

How does tirzepatide compare to retatrutide?

Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist. The additional glucagon receptor activity in retatrutide adds hepatic glucose production effects and thermogenic energy expenditure — contributing to the even higher weight reduction observed in retatrutide's Phase II data (24% vs tirzepatide's 22.5% in obesity trials). For research requiring isolated dual-incretin pharmacology without glucagon receptor contribution, tirzepatide is the appropriate compound.

What is the storage protocol for tirzepatide?

Lyophilized tirzepatide is stable at −20°C. Once reconstituted, store at 2–8°C and use within 30 days. Avoid vigorous shaking during reconstitution — the fatty acid conjugate makes aggregation possible under mechanical stress. Reconstitute by adding bacteriostatic water slowly and swirling gently.